2019

LEADERSHIP COURSE

ASTCT
American Society for
Transplantation and Cellular Therapy

ASTCT
American Society for
Transplantation and Cellular Therapy

ASTCT Leadership Course May 2 – 3, 2019 | Chicago, IL

Hello,

Welcome to the inaugural American Society of Transplantation and Cellular Therapy Leadership Course! We received an overwhelming response and are really excited about those who will be attending this course. The future of blood and marrow transplantation and cellular therapy is dependent on the involvement and leadership of all members within the field. You stand out as the future of our field, and I believe you will contribute important dialogue to this course.

I hope this course provides a stepping stone in your career path as a member of the transplantation and cellular therapy field. The course includes interactive presentations by faculty members, along with follow-up discussions. The faculty will also present their biographies, career stories, and personal anecdotes during an informal dinner. In addition to attending the in person meeting, you will participate in 2-3 follow up webinars throughout of the course of the year.

I am looking forward to meeting you in Chicago!

Welcome to the 2019 Leadership Course,
Navneet Majhail, MD, MS

ASTCT
American Society for
Transplantation and Cellular Therapy

Meet the Faculty
(Complete faculty bios begin on page 11)

Michael Capaldi, MEd
Sanofi-Genzyme
Bridgewater, NJ

Clint Divine, MBA
University of Kansas
Cancer Center
Kansas City, KS

Stella Davies, MBBS, PhD, MRCP
Cincinnati Children's
Hospital
Cincinnati, OH

Gary Goldstein, BA
Stanford Health Care
Palo Alto, CA

Steven Devine, MD
Center for International Blood &
Marrow Transplant Research/Be the Match
Minneapolis, MN

ASTCT
American Society for
Transplantation and Cellular Therapy

Sergio Giralt, MD
Memorial Sloan
Kettering Cancer Center
New York City, NY

C. Fred LeMaistre, MD
Sarah Cannon
Nashville, TN

Dianna Howard, MD
Wake Forest University
Comprehensive Cancer
Center
Winston-Salem, NC

Joseph Mikhael, MD,
MEd, FRCPC, FACP
City of Hope Cancer
Center
Duarte, CA

Colette Huzinec, BA
SmithBucklin
Chicago, IL

Sophie Paczesny, MD, PhD
Indiana University School of
Medicine
Indianapolis, IN

ASTCT
American Society for
Transplantation and Cellular Therapy

2019 Leadership Course Participants

Rachel Cook, MD, Oregon Health and Science University, Portland, Oregon

Dr. Rachel Cook is a leukemia and bone marrow transplant doctor at Oregon Health and Science University where she is the site director for the Acute Leukemia Research Program. She completed her residency and chief residency at Mayo Clinic in Rochester, Minnesota and her hematology/oncology fellowship at the University of Pennsylvania in Philadelphia, Pennsylvania where she also completed a masters in health policy research. She is interested in improving options for treatment of high-risk leukemias and improving decision making around and outcomes for bone marrow transplant.

Betty Ky Hamilton, MD, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio

Betty Ky Hamilton is the Associate Director of the Blood and Marrow Transplant Program and Assistant Professor of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Hamilton received her medical degree from the University of Chicago and internal medicine residency training at the Hospital of the University of Pennsylvania. She completed her hematology/oncology fellowship at the Cleveland Clinic and subsequently joined as a Staff Physician in the Department of Hematology and Medical Oncology. Dr. Hamilton's clinical and research interests focus on the use of allogeneic transplantation in the treatment of hematologic malignancies; and improving outcomes post-transplant, specifically in graft-versus-host disease and long-term follow up/survivorship.

Jennifer Kanakry, MD, National Cancer Institute, Washington D.C

Dr. Jennifer Kanakry is an Assistant Research Physician at the Center for Cancer Research of the National Cancer Institute of the National Institutes of Health. Dr. Kanakry received her B.A. (2002) from Pomona College in Claremont, California, where she studied cognitive neuropsychology and biology. She then worked at the NIH in Bethesda, Maryland as an Intramural Research Training Award Fellow under Dr. Ellen Leibenluft within the Mood and Anxiety Disorders Program of the National Institute of Mental Health. She then went on to receive her medical degree (2007) from a joint program between Dartmouth College School of Medicine (Hanover, NH) and Brown University School of Medicine (Providence, RI). She completed both her residency training in Internal Medicine (2007-2010) and fellowship training (2010-2013) in Hematology at Johns Hopkins Hospital. Her clinical research during fellowship was focused on virus-associated cancers, immunodeficiency associated lymphomas, and allogeneic hematopoietic cell transplantation under the mentorship of Dr. Richard Ambinder. In 2013, she joined the faculty at Johns Hopkins

within the Departments of Medicine and Oncology, where she primarily focused on treating patients with diseases that more commonly occur in the setting of immunodeficiency, including lymphoma, disorders of immune dysregulation, and virus-associated lymphoproliferative disorders. She continued her research on EBV- and KSHV-related cancers, investigating biomarkers for these diseases and carrying out clinical trials for patients with these cancers. In 2015, she joined the Experimental Transplantation and Immunology Branch of the National Cancer Institute, where she continues to focus on diseases related to immunodeficiency and the role of allogeneic bone marrow transplantation and other adoptive immunotherapies. At present, she serves as the Clinical Head of Transplant for the Branch and oversees the clinical care of patients on branch protocols, which include trials of allogeneic transplant, immune checkpoint inhibitors, CAR T-cells, TCR gene engineered cells for a variety of malignant and non-malignant diseases. She has two open clinical trials of allogeneic hematopoietic cell transplantation for primary immunodeficiency diseases, both studying novel approaches to potentially improving engraftment, reducing toxicity, and securing robust immune reconstitution through reduced-intensity conditioning approaches. She also recently opened a clinical trial of allogeneic hematopoietic cell transplantation for patients with peripheral T cell lymphoma. In addition, she engages in retrospective research related to viral complications of allogeneic hematopoietic cell transplantation, with a particular focus on EBV and CMV.

Alla Keyzner, MD, Mount Sinai, New York City, New York

Dr. Alla Keyzner earned her medical degree at the Drexel University College of Medicine in Philadelphia, PA. Following graduation from internal medicine residency and hematology/oncology fellowship at the Icahn School of Medicine at Mount Sinai in New York City she went on to complete an additional year of BMT fellowship at Mayo Clinic College of Medicine and Science in Rochester, MN. Upon conclusion of her training, Dr. Keyzner joined Northwell faculty (formerly known as North Shore-LIJ) as an attending in the Bone Marrow Transplant group. Five years ago, Dr. Keyzner joined the Mount Sinai faculty as an attending at the Bone Marrow Transplant group. Dr. Keyzner has developed a strong expertise in allogeneic stem cell transplantation of myelofibrosis as well as use of alternative donors in bone marrow transplantation. In June 2018, Dr. Keyzner became an associated director of allogeneic stem cell program at Tisch Cancer Institute Bone Marrow & Stem Cell Transplantation.

Michelle Lee, MD, PhD, Children's Hospital at Montefiore, Bronx, New York

Michelle A. Lee is an Attending Physician in the Division of Hematology, Oncology, and Marrow & Blood Cell Transplantation at the Children's Hospital at Montefiore in Bronx, NY. She is the Interim Director of the Marrow & Blood Cell Transplantation Program and an Assistant Professor at Albert Einstein College of Medicine. Michelle graduated from Spelman College in Atlanta, Georgia with a BS in Biology, before she earned MD and PhD degrees from Harvard Medical School. She completed internship/residency training in General Pediatrics at The Children's Hospital of Philadelphia. Then she completed fellowship training in Pediatric Hematology-Oncology and afterwards was an Instructor at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

Michelle has developed clinical expertise in transplantation for non-malignant conditions including hemoglobinopathies. With other members of the non-profit organization STAR - Sickle Cell Transplant Advocacy and Research Alliance, her goal is to make transplant safer so that it can be utilized more readily as a

treatment to cure children with sickle cell disease. More broadly, her interest is understanding and then addressing the mechanisms by which biological differences and social challenges contribute to disparities in transplant outcomes related to the recipient's race and ethnicity.

Mylove Mortel, BS, BSN, MS, University of Chicago Medicine, Chicago, Illinois

My passion for transplant and cellular therapy can be traced back to that fateful interview I had in 2008 during which I casually picked up a magazine while waiting for the HR recruiter to interview me for my first nursing position. The magazine had a profile on stem cell transplant, and I vividly remember reading about the therapy as "revolutionary" and "ground-breaking". Piqued, I asked the recruiter if they had a position open in stem cell transplant. As luck would have it, the BMT unit had an opening and I found myself a few weeks later standing as a newly minted nurse on that floor. Flash-forward to the present time 11 years later, I am currently the program nurse manager for the University of Chicago Medicine Hematopoietic Cellular Therapy Program. I have been in this role since 2014. In this role I oversee the clinical operations for BMT and cell therapy on the ambulatory side of things and manage our nurse coordinators, donor coordinators, and data managers. I was actively involved in the development of our CAR T-cell therapy program and still am heavily involved in the intermediate and long-term planning for the growth of our combined BMT and cell therapy programs. I enjoy the connections that I have with patients and my team members and I remain just as passionate about transplant as I was in 2008 (which could explain why I haven't left this specialty since my first nursing job).

Before my nursing career, I completed my undergraduate degree in mathematics and briefly worked as an actuarial analyst before becoming a sales manager for a food distributor. These experiences have instilled in me a great appreciation for people management as well as provided me with good grounding on data analytics. In 2011 I pursued a graduate degree in public health with a focus on epidemiology to combine my love of math and nursing.

Outside of work, I enjoy spending time with my 3-year old daughter and my husband. I consider being a "mom" my greatest responsibility on earth.

Pritesh Patel, MD, CHB, University of Illinois at Chicago, Chicago, Illinois

Dr. Patel obtained his medical degree at the University of Manchester Medical School, UK. He completed his residency and chief residency at Cook County Hospital and his fellowship at the UIC (University of Illinois at Chicago). He has been a faculty member at UIC since 2011 where his clinical practice and research has focused on malignant hematology and stem cell transplant. He is currently an Associate Professor and the Associate Director of the Blood and Marrow Transplant Program.

Muthalagu Ramanathan, MBBS, University of Massachusetts, Boston, Massachusetts

My career goal is to research and develop novel transplant and non-transplant therapeutic strategies to cure hematological malignancies. I care for patients with hematological malignancies before during and after stem cell transplant. I find the varied clinical presentations, diagnostic, management challenges involved in the treatment of hematological malignancies fascinating and caring for these patients extremely gratifying. I'm the Director of Myeloma Program and the Codirector of the Stem Cell Transplant Program at UMass. In this capacity, I lead the multi-disciplinary weekly "Bone Marrow Transplant (BMT) continuing medical education case conference" and the "Transplant Patient Care Coordination Meeting." I'm in charge of the quarterly quality meetings and responsible for maintaining FACT accreditation at our institution. Some of the skills I hope to build through this Leadership Course include learning how to be authoritative yet approachable while managing a team, how to have difficult conversations with ease, how to advocate for the program and diplomatically negotiate with administration.

Craig Sauter, MD, Memorial Sloan-Kettering Cancer Center, New York City, New York

Dr. Sauter is an Assistant Attending and the Clinical Director of the Adult BMT Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC). His research has focused on improving the outcome of patients with relapsed and refractory (rel/ref) non-Hodgkin lymphoma (NHL) with hematopoietic cell transplantation (HCT). He has reported on successive phase II studies for allogeneic HCT in NHL patients. He has also investigated prognostic factors based upon imaging, both functional and computed tomography, that have predicted outcomes in these studies. He is currently introducing novel therapeutics, both pharmacologic and cellular, into salvage and HCT platforms of both autologous and allogeneic graft sources for rel/ref NHL patients. As Clinical Director, he is focusing on improving efficiency and quality of life, while enabling liberated time and effort of academic pursuits, for his academic practitioner colleagues.

Jodi Skiles, MD, MS, Indiana University School of Medicine, Indianapolis, Indiana

Dr. Jodi Skiles is a native-born Hoosier. She grew up in Indiana and has completed all her training – undergraduate, medical school, residency, and fellowship – in Indiana. Upon completion of fellowship, she joined the section of Pediatric Hematology/Oncology at Indiana University School of Medicine at Riley Hospital for Children in 2012. Since joining faculty, she has served in several leadership positions including Pediatric Hematology/Oncology Fellowship Program Associate Director (2015-2017) as well as Director (2017-present). She also spearheaded an effort to begin offering fertility preservation counseling to pediatric cancer patients, which has now culminated in her role as Director of Fertility Preservation Services for the NCI-designated Indiana University Simon Cancer Center. Over the past 2 years, she has been leading an effort to create an Adolescent and Young Adult Oncology Program at Indiana University. She has also been a lead clinical collaborator on multiple BMT CTN and CIBMTR studies and is partially funded by a U54 grant evaluating biomarkers of sinusoidal obstructive syndrome in pediatric transplant patients. In July 2018, she was appointed Director of the Pediatric Stem Cell Transplant Program at Riley Hospital for Children. In the short time that she has been in this role, she has been instrumental in

collaborating with her adult transplant colleagues to launch CAR-T cell therapy at Indiana University Simon Cancer Center and she is actively working to bring clinical research studies for CAR-T therapy to Riley Hospital to advance the field of immune effector cell therapy. In her free time, Dr. Skiles enjoys soaking every minute with her two princess-obsessed girls and unbelievably supportive husband.

Lori Stover, RN, BSN, MBA, Allegheny Health Network, Pittsburgh, Pennsylvania

Lori Stover, RN, BSN, MBA is the Administrative Director of the Division of Hematology & Cellular Therapy at the Allegheny Health Network in Pittsburgh, Pennsylvania. As Administrative Director for the Division, Lori oversees all operations related to FACT accreditation and quality management. She is also responsible for administrative support for all physicians and ancillary personnel. Prior to her work in Hematology, Ms. Stover was a Research Program Leader for the Melanoma Center at the University of Pittsburgh Medical Center and spoke on the use of various immunotherapies for the management of this disease. She is a board member for the Leukemia & Lymphoma Society of Western Pennsylvania and is also active in various patient activities for the Division. She received her Bachelors of Science degree in Nursing from Gannon University in Erie, Pennsylvania and her MBA at Point Park University in Pittsburgh, Pennsylvania.

Brandon Triplett, MD, St. Jude Children's Research Hospital, Memphis, Tennessee

Dr. Brandon Triplett, MD, received his medical degree and pediatric training at St. Louis University School of Medicine in St. Louis, Missouri. He then matriculated to St. Jude Children's Research Hospital in Memphis, Tennessee for Pediatric Hematology/Oncology/Transplantation training, where he studied NK cell biology and post-transplant immune reconstitution. Upon completion of his training, Dr. Triplett returned to St. Louis University as a pediatric Hematologist, Oncologist, and Transplanter, and became Medical Director of the St. Louis Cord Blood Bank. In 2009, Dr. Triplett returned to St. Jude, to focus his efforts on hematopoietic cell transplantation and cellular therapies. His primary research emphasis is on the development of therapeutic haploidentical donor transplantation trials for patients with relapsed and refractory hematologic malignancies. During his time at St. Jude, he has advanced to Associate Member in the Department of Bone Marrow Transplantation and Cellular Therapy, and has been appointed Chief of the Transplant Clinical Service and Director of the BMT Fellowship program.

ASTCT
American Society for
Transplantation and Cellular Therapy

Program Schedule

Day 1: Thursday, May 2, 2019

Time	Session
7:00AM – 8:00AM	Breakfast and registration at ASTCT Headquarters (330 N. Wabash Ave, 14th floor)
8:00AM – 8:30AM	**Welcome and Introductions** Navneet Majhail, MD, MS, Cleveland Clinic
8:30AM – 10:00AM	**Self-Awareness – The Foundation of Leadership** Colette Huzinec, BA, SmithBucklin *Review results of a personality assessment (the MPP) and learn how your innate biases and comfort zones influence how you think, feel and behave*
10:00AM – 10:30AM	Break
10:30AM – 12:00PM	**Leading Teams for Results** Michael Capaldi, MEd, Sanofi-Genzyme *Skills and strategies for leading successful teams; participants will reflect on personal experiences with high-performing teams and build upon those experiences as they develop their own leadership style*
12:00PM – 12:30PM	Lunch
12:30PM – 1:30PM	**The Good, The Bad, and The Ugly – A Day in the Life of a BMT Program Director** Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center *The "job description" challenges and opportunities for leaders of BMT and cell therapy programs*
1:30PM – 2:30PM	**The Business of BMT and Cell Therapy** C. Fred LeMaistre, MD, Sarah Cannon *Demonstrating program value, understanding financials, building relationships, managing capacity and planning for growth*
2:30PM – 3:30PM	**Best Buddies! Working with Your BMT Program Administrator** Clint Divine, MBA, MSM, Kansas University Medical Center *Private payer, Medicare and Medicaid payment mechanisms for BMT and cell therapy*
3:30PM – 3:45PM	Break
3:45 PM – 4:45 PM	**Show Me the Money** Gary Goldstein, BA, Stanford University *Private payer, Medicare and Medicaid payment mechanisms for BMT and cell therapy*
4:45PM – 5:00PM	Wrap Up for Day 1
6:00PM to 9:00PM	**Reception, Dinner – Career Development Discussion** *Panel discussion with course faculty at Quartino Ristorante (626 N. State St)*

Program Schedule

Day 2: Friday, May 3, 2019

Time	Session
7:00AM – 8:00AM	Breakfast at ASTCT Headquarters (330 N. Wabash Ave, 14th floor)
8:00AM – 9:00AM	**It's All About the People: Recruitment and Mentorship** Stella Davies, MD, Cincinnati Children's Hospital *Recruitment and retention of personnel and mentoring team members for success*
9:00AM – 10:30AM	**Saying it Aloud! Using Communication and Media for Promoting Self and Your Program** Joseph Mikhael, MD, City of Hope Cancer Center *Using various media platforms to share information about yourself and your program*
10:30AM – 11:00AM	Break
11:00AM – 12:00PM	**Managing the Research Enterprise** Steven Devine, MD, CIBMTR/BeTheMatch *Overview of CIBMTR and BMT CTN, managing infrastructure and personnel for conducting research, and opportunities and challenges in developing and sustaining a successful research program in BMT and cell therapy*
12:00PM – 1:00PM	**From the Bench to the Bedside: Translational BMT and Cell Therapy Trials** Sophie Paczesny, MD, Indiana University School of Medicine *Establishing a translational and early phase trial program in BMT and cell therapy and the logistics of obtaining resources and funding for conducting such research*
1:00PM – 1:30PM	Lunch
1:30PM – 2:30PM	**Let's Get Partisan Towards BMT: Advocacy at the Local and National Level** Dianna Howard, MD, Wake Forest University *Role of advocacy in shaping policy and reimbursement for BMT and cell therapy*
2:30PM – 3:00PM	Wrap up for day 2 Navneet Majhail, MD, MS, Cleveland Clinic

Navneet Majhail, MD, MS
Director, Blood & Marrow Transplant Program
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio

Dr Navneet Majhail is the Director of the Blood & Marrow Transplant Program at the Taussig Cancer Institute, Cleveland Clinic, and Professor at the Cleveland Clinic Lerner College of Medicine. He has received medical training at the Government Medical College in Chandigarh (India), the All India Institute of Medical Sciences in New Delhi, the Cleveland Clinic Foundation, and the University of Minnesota in Minneapolis. After completing his fellowship training in Hematology-Oncology, Dr Majhail joined the University of Minnesota as Assistant Professor with their Blood and Marrow Transplant Program. Subsequently, and prior to joining the Cleveland Clinic, he was Medical Director, Health Services Research with the National Marrow Donor Program and an Adjunct Associate Professor of Medicine with the University of Minnesota. Dr Majhail specializes in the care of adult patients receiving blood and marrow transplantation. His research focuses on health services and health policy issues in blood and marrow transplantation and quality of life and late effects in transplant survivors.

Michael Capaldi, MEd
Head of Public Affairs, Oncology & Transplant
Sanofi-Genzyme
Bridgewater, New Jersey

Mike Capaldi is Head of Public Affairs, Oncology & Transplant for Sanofi-Genzyme in his 22nd year with the organization.

In this role, Mike interfaces with important healthcare stakeholders in order to bolster Sanofi's commitment to work passionately, every day, to understand and solve healthcare needs of people across the world.

His experience in external affairs includes partnering with appropriate trade associations and external policy coalition groups on important industry issues. Mike has also led Sanofi's grassroots platform and employee PAC which allows colleagues to engage in civic action. Finally, he was a member of the state government affairs team monitoring the legislative landscape in Connecticut, Maine, New Hampshire, Rhode Island and Vermont.

Mike has a broad set of experiences at Sanofi including work in Sales, Corporate Social Responsibility and Training & Development for 12 years where he was responsible for the T&D of nearly 10,000 field and headquarter-based employees. Mike served as President of the Society of Pharmaceutical and Biotech Trainers (now L-TEN) in 2010-11. In 2007, he earned a Masters of Education in Corporate Training & Knowledge Management from Jones International University.

Stella Davies, MBBS, PhD, MRCP
Director, Division of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children's Hospital
Cincinnati, Ohio

I am a professor of pediatrics and director of the bone marrow transplant program at Cincinnati Children's Hospital. I started my career as an internist at the Royal Victoria Infirmary in Newcastle-upon-Tyne, England. I got side-tracked by an elective in pediatrics, when I discovered a fondness for patients one can carry around, and by an elective in Minnesota where I met my husband and, as my mother would say "got stuck there". I am an active clinician and enjoy in-patient attending (really!). I have run an NIH funded laboratory for over 20 years, with a focus on early and late toxicities of bone marrow transplant, with a current focus on mechanisms of endothelial injury leading to complications such as GVHD and TMA. I believe strongly that research is the antidote to professional burnout, and mentor nurses, dieticians and chaplains, all of whom have presented IRB-approved prospective research studies at the ASBMT annual meeting.

I have been active nationally in the transplant community, having been an active member of ASBMT for over 20 years and serving as a faculty member and then chair of the ASBMT clinical research training course for 6 years. I have been fortunate enough to be a scientific chair of the ASBMT annual meeting on two occasions. I have also been a member of the NMDP board of directors, chair of the CIBMTR advisory board, chair of the CIBMTR pediatric cancer committee, and a permanent member of the NIH clinical oncology study section.

Steven Devine, MD
Senior Vice President for Research
National Marrow Donor Program (NMDP)/Be The Match
Associate Scientific Director
Center for International Blood and Marrow Transplant Research (CIBMTR)
Minneapolis, Minnesota

Steven Devine MD is currently Senior Vice President for Research at the National Marrow Donor Program (NMDP)/Be The Match and Associate Scientific Director at the Center for International Blood and Marrow Transplant Research (CIBMTR). He served for eight years as Chair of the National Cancer Institute funded Alliance Transplant Committee as well as a 2-year term as Chair of the NIH-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Steering Committee. He is currently one of the three Co-PIs for the BMT CTN Data Coordinating Center. He was previously the Principal Investigator of The Ohio State Consortium, one of the 20 core members within the BMT CTN. He was the 2017 Track leader in Leukemia, myelodysplastic syndrome, and transplantation educational sessions at the American Society of Clinical Oncology (ASCO) annual meeting and co-authored the 2017 ASCO Cancer Clinical Advances position paper. He has a major research interest in the application of stem cell transplantation for patients with acute leukemia and non-Hodgkin's lymphoma and has served as Chair of two multi-center NIH-supported clinical transplantation trials in AML. He has a major interest in developing novel methods to mobilize hematopoietic stem cells from both patients and donors. He has written or co-written more than 200 peer-reviewed papers and more than 350 abstracts as well as several reviews and book chapters in the field of stem cell transplantation, leukemia, and hematology. He is an Associate Editor for *Biology of Blood and Marrow Transplantation* and he has served as a reviewer for several journals, including *Blood, Journal of Clinical Oncology, New England Journal of Medicine, Nature Medicine, Haematologica,* and *Bone Marrow Transplantation.*

Clint Divine, MBA
Senior Director, Division of Hematologic Malignancies and Cellular Therapy
University of Kansas Cancer Center
Kansas City, Kansas

Clint Divine is the Senior Director for the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Cancer Center. He holds a Bachelor of Science from Southern Oregon University and Masters of Business Administration from Baker University. Clint has worked in the blood and marrow transplantation field for 17 years, beginning as a transplant analyst. He is an active member of multiple academic committees including serving as the chair of the American Society for Transplantation and Cellular Therapy (ASTCT) Administrative Directors Special Interest Group (SIG).

Gary A. Goldstein, BA
Business Manager, Adult BMT Program
Stanford Health Care
Palo Alto, California

Gary Goldstein is the Business Manager for the adult BMT program at Stanford Health Care. He holds a degree in Business Economics from the University of California, Santa Barbara and has 30 years of experience in health care finance. He has been with the Blood & Marrow Transplant Program at Stanford since 1995, and has helped lead the program's growth in performing cancer cellular therapy.

Gary was a member of the National Marrow Donor Program's Board of Directors from 2009 to 2014, and re-joined the Board of Directors in 2017 when he became the President and Chair of the NMDP Council Advisory Group. Gary also serves as a current member of the NMDP Audit & Finance Committee, the ASTCT Government Affairs Committee, and the ASTCT Cellular Therapy Coding Task Force. Gary was a matched, unrelated bone marrow donor through the NMDP in 1997.

Sergio Giralt, MD
Adult Bone Marrow Transplant Service, Chief
Memorial Sloan Kettering Cancer Center
New York City, New York

Dr. Giralt has been involved in the field of hematopoietic cell transplantation (HCT) for more than 20 years. Dr Giralt trained at MD Anderson Cancer Center under the mentorship of Dr Richard Champlin. Since 2010 he is the Chief of the Adult Bone Marrow Transplant (BMT) Service at Memorial Sloan Kettering Cancer Center. Dr. Giralt has held leadership positions in major national organizations such as the Center for International Blood and Marrow Transplant Research (Chair of the Advisory Board), the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN), and most recently President of the American Society of Blood and Marrow Transplantation. His clinical research career has focused on the following areas: 1) Developing better tolerated conditioning regimens for older or medically infirmed patients with hematological malignancies to allow them access to this procedure; 2) Developing novel HCT therapies (conditioning regimens plus post-transplant therapies) for autologous and allogeneic HCT for myeloma and 3) Pursue strategies that will significantly reduce HCT symptom burden and toxicities. Dr Giralt has mentored numerous current and future leaders in the field and is an internationally recognized figure in HCT.

ASTCT
American Society for
Transplantation and Cellular Therapy

Dianna Howard, MD
Director, Stem Cell Transplant and Cell Therapy Program
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina

Dianna S. Howard, MD, is the Director of the Wake Forest University Comprehensive Cancer Center (WFU-CCC) Stem Cell Transplant and Cell Therapy Program and a senior investigator in the Leukemia Program. She has focused her career on the care of patients with hematologic malignancies and those for who transplant and cellular therapy are modalities of care. Dr. Howard's experience includes oversight for multiple cooperative group clinical trials in hematologic malignancies and stem cell transplant; pharmaceutical sponsored trials including novel agents in GVHD; and, investigator initiated translational projects focused on defining unique targets on leukemia stem cells. For the last several years Dr. Howard has been involved in administrative and leadership roles at the University of Kentucky and subsequently, at Wake Forest. As a program director, she has evolved her focus on quality outcomes with transplant, reimbursement mechanisms, patient access to care, and advocacy through health care policy. Dr. Howard serves on ASH Government Relations Committee, ASBMT Quality Outcomes Committee, is the ASBMT representative to the American College of Physicians Council of Subspecialists, and Co-Chairs the ASBMT Government Relations Committee.

Colette Huzinec, BA
Senior Vice President & Chief Human Resources Officer
SmithBucklin
Chicago, Illinois

As Senior Vice President & Chief Human Resources Officer, Colette provides strategic and operational leadership for all human resources functions, including oversight of the company's talent acquisition, engagement and management initiatives, and articulating, protecting and advocating the SmithBucklin culture. She joined the company in 2004 responsible for talent development and training. Prior to joining SmithBucklin, Colette served as human performance manager at Accenture where she consulted for Fortune 500 companies. Colette holds a double bachelor's degree in psychology and business studies from the University of Leeds in England.

C. Fred LeMaistre, MD
Senior Vice President & Physician in Chief of Hematology and Hematopoietic Cell Therapy
Sarah Cannon
Nashville, Tennesee

C. Frederick LeMaistre, MD, is the Senior Vice President and Physician in Chief of Hematology and Hematopoietic Cell Therapy, Sarah Cannon. He received his medical training from Southwestern Medical School, where he also trained in internal medicine. Dr. LeMaistre performed a fellowship in hematology and oncology at the University of Texas Health Science Center at San Antonio. He is board certified in both internal medicine and medical oncology.

In 1984, Dr. LeMaistre joined the faculty at the University of Texas Health Science Center in San Antonio, where he established the institution's first marrow transplant program. In 1988, he established the section of experimental therapy in the division of hematology at the M.D. Anderson Cancer Center. In 1993, he established the Texas Transplant Institute in San Antonio which now encompasses nationally recognized programs in kidney, liver and heart transplant as well as adult and pediatric stem cell transplant. In 2009, the Texas Transplant Institute expanded to become the Texas Institute of Medicine and Surgery, a multi-specialty physician organization associated with the Methodist Healthcare System in San Antonio. In 2012, he moved to Nashville to assume his current position. Sarah Cannon is the cancer institute of Hospital Corporation of America (HCA), offering integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Dr. LeMaistre leads the development of overall cancer services in 15 core Sarah Cannon markets as well as the Sarah Cannon Blood Cancer Network which will transplant over 1,200 patients this year.

Dr. LeMaistre has been active in clinical research throughout his career. He is a founding member and immediate past president of the Foundation for the Accreditation of Cell Therapy (FACT). He is also past President of the Board of the American Society for Transplantation and Cellular Therapy (ASTCT).

Joseph Mikhael, MD, MEd, FRCPC, FACP
Applied Cancer Research & Drug Discovery Division, Professor
Translational Genomics Research Institute, City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Phoenix, Arizona

Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF). He facilitates and promotes myeloma research worldwide, especially in underprivileged countries.

Dr. Mikhael is a consultant hematologist and Director of Myeloma Research at the HonorHealth Research Institute where he conducts phase 1 clinical trials. He also serves as a Councilor on the Executive of the American Society of Hematology. He also recently led the ASCO guidelines for multiple myeloma.

Dr. Mikhael was recently a hematologist at Mayo Clinic Arizona where he served as a Professor at the Mayo College of Medicine, Associate Dean of Graduate Medical Education and Deputy Director - Education of the Mayo Clinic Cancer Center. He has been recognized with numerous awards in education including being in the Mayo Clinic Resident and Fellow Association Hall of Fame as Educator of the Year. He was also recently named in the Top 100 Doctors in the United States.

He specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom's macroglobulinemia. Dr. Mikhael is currently the principal investigator of many clinical trials, primarily in multiple myeloma. His other clinical research interests also include pharmaco-economics, communication skills and media relations. He has published over 150 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group, and serves on the editorial board of the Journal of Clinical Oncology.

Sophie Paczesny, MD, PhD
Professor of Pediatrics and Immunology
Indiana University School of Medicine
Indianapolis, Indiana

Sophie Paczesny, MD, PhD, is a Professor of Pediatrics and Immunology at Indiana University School of Medicine. She received her MD degree at the University of Strasbourg, France. She is board certified in Pediatrics and Hematology/Oncology and obtained a PhD in Tumor Immunology from the University of Paris, France and The Baylor Institute for Immunology, Dallas, TX. Dr. Paczesny worked in Paris, France before moving to the University of Michigan in 2006 as post-doctoral fellow and then assistant professor. In 2012, she started work at Indiana University. Dr. Paczesny is currently the Nora Letzter Professor of Pediatrics, a full member of the Indiana University Simon Cancer Center, leads the Biomarkers Stem Cell Transplantation Program. She has also an International Joint Appointment at the Nice-Sophia Antipolis University School of Medicine, France.

She is member of the American Society for Clinical Investigation and ASCI councilor, co-chair of the Centre for International Blood and Marrow Transplant Research immunobiology working group, and co-chair on the ASH task force on immunotherapies. Dr. Paczesny's research has focused on three areas: 1) developing and translating biomarkers for the outcomes following allogeneic hematopoietic stem cell transplantation; 2) discovering inhibitors of drug targetable biomarkers; and 3) finding novel therapies to treat graft-versus-host disease and improve graft-versus-leukemia including cellular therapies.